- Company
- Neutropenia drugs' sales affected by their sales partners
- by Chon, Seung-Hyun Jun 7, 2022 06:04am
- GC Pharma and Kyowa Kirin are fiercely competing for the lead in the neutropenia treatment market in Korea. At the end of last year, GC Pharma’s Neulapeg had risen to the lead for the first time in 7 years, but Kyowa Kirin has again taken over the lead with Neulasta. The addition of Boryung’s sales power to the products is affecting the sales
- Company
- Emgality passes DREC review… what about Ajovy?
- by Eo, Yun-Ho Jun 7, 2022 06:04am
- With Emgality nearing insurance reimbursement in Korea, what path Ajovy will walk is also gaining attention. Teva-Handok Pharma had applied for the reimbursement of its calcitonin gene-related peptide (CGRP) targeting migraine drug Ajovy (fremanezumab) earlier this year. However, Ajovy’s reimbursement was not deliberated as an agenda at
- Company
- Cumulative sales of Spinraza in 3yrs is ₩200 billion
- by Chon, Seung-Hyun Jun 7, 2022 06:03am
- Spinraza, a rare disease treatment, posted 200 billion won in sales over the past three years after registering health insurance benefits. Although there is not much demand, it has achieved high performance in a short period of time due to the nature of expensive treatments worth nearly 100 million won per bottle. According to IQVIA, a pharma
- Company
- Bio USA to be held offline for the first time in 3 years
- by Kim, Jin-Gu Jun 3, 2022 06:37am
- The Bio International Convention (BIO USA),’ which is known as one of the largest global events in the biotechnology industry, is set to be held in San Diego USA from the 13th to the 16th of this month. Twenty or more pharma and bio companies in Korea including Samsung Biologics, Celltrion, SK Pharmteco, and Lotte Biologics are plannin
- Company
- Pharmas succeed in additionally avoiding Entresto patent
- by Kim, Jin-Gu Jun 3, 2022 06:37am
- Domestic pharmaceutical companies have succeeded in additionally avoiding the patent of Novartis’s heart failure treatment ‘Entresto.’ According to industry sources on the 2nd, the Intellectual Property Trial and Appeal Board recently ruled that the claims were established in the trial to confirm the passive scope of rights on Entresto
- Company
- 10 years since stem cell therapy was introduced
- by Chon, Seung-Hyun Jun 3, 2022 06:36am
- Ten years have passed since stem cell treatments appeared in Korea, but they have yet to produce commercial results. Medipost's CARTISTEM is recording annual sales of 10 billion won in Korea, but there is virtually no overseas sales. According to the Financial Supervisory Service on the 2nd, Medipost's sales of stem cell treatments in the
- Company
- Dukarb of Huons won the patent battle
- by Kim, Jin-Gu Jun 3, 2022 06:36am
- Given that Boryung won a series of previous referees, the pharmaceutical industry is paying keen attention to the decision, which is the opposite of the previous one. ◆Patent judge decides opposite to previous judgment According to the pharmaceutical industry on the 2nd, the Korean Intellectual Property Tribunal made a claim c
- Company
- Commercialization of ADC Enhertu is imminent in Korea
- by Eo, Yun-Ho Jun 2, 2022 05:58am
- The HER2-directed antibody-drug conjugate (ADC) ‘Enhertu’ is expected to be commercialized in Korea soon. According to inducts sources, Daiichi Sankyo Korea and AstraZeneca Korea’s human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate (ADC) ‘Enhertu (trastuzumab deruxtecan),’ is expected to be approved withi
- Company
- Evusheld to be introduced in Korea
- by Eo, Yun-Ho May 31, 2022 06:06am
- The introduction of the COVID-19 prevention drug Evusheld in Korea has been confirmed. The KDCA supplementary budget of 4.9083 trillion won was confirmed yesterday (29th), which includes securing a shortage of living support, paid vacation expenses, quarantine hospitalization, and home treatment expenses due to a surge in confirmed cases. The
- Company
- Handok to “speed up global P2T for its BTC candidate"
- by Kim, Jin-Gu May 31, 2022 06:05am
- Handok Pharmaceuticals announced on the 30th that it had recently received approval to change the clinical trial protocol for its candidate, 'ABL001(CTX-009),' which the company is developing as a treatment for biliary tract cancer, to expand the trial overseas into a global clinical trial. ABL001 is a next-generation anticancer drug that
